Literature DB >> 2905253

Effects of roxatidine acetate on 24-hour gastric acidity. Early evening versus bedtime administration in healthy subjects.

P Hemery1, P Congard, J P Galmiche, S Bonfils.   

Abstract

The gastric antisecretory activity of roxatidine acetate was studied on 24-hour intragastric pH in 12 healthy male volunteers. The study was randomised, double-blind and double-dummy where either roxatidine acetate 150 mg as a slow release granulated formulation or placebo were administered at 7.30 pm or 10 pm. Roxatidine acetate 150 mg produced a significant decrease in the number of hours during which gastric acidity ranged between pH 1.5 and 4.0 which was consistent with the pharmacokinetic profile of the drug. There was no significant difference between the median intragastric pH values for early evening and bedtime administration of roxatidine acetate. The present data confirm that roxatidine acetate 150 mg inhibits gastric acid secretion but while a single evening dose is effective in controlling intragastric pH the results suggest there is no clear advantage in an early evening dose compared with a bedtime dose.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2905253     DOI: 10.2165/00003495-198800353-00014

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  9 in total

1.  The effects of roxatidine acetate on 24-hour intragastric acidity. Investigations in healthy volunteers and comparison with ranitidine and placebo.

Authors:  H S Merki; L Witzel; D Kaufmann; M Kempf; J Neumann; E Scheurle; J Röhmel; R P Walt
Journal:  Drugs       Date:  1988       Impact factor: 9.546

Review 2.  Interaction of roxatidine acetate with antacids, food and other drugs.

Authors:  R A Labs
Journal:  Drugs       Date:  1988       Impact factor: 9.546

3.  [Ranitidine effects on 24-hour intragastric pH in normal individuals. Interest of continuous monitoring for selection of an optimal therapeutic regimen (author's transl)].

Authors:  J P Galmiche; T Vallot; S Mayeur; D Arsène; P Ducrotte; P Duvaldestin; M Mignon
Journal:  Gastroenterol Clin Biol       Date:  1982-04

4.  Long-term ambulatory gastric pH monitoring: validation of a new method and effect of H2-antagonists.

Authors:  C J Fimmel; A Etienne; T Cilluffo; C von Ritter; T Gasser; J P Rey; P Caradonna-Moscatelli; F Sabbatini; F Pace; H W Bühler
Journal:  Gastroenterology       Date:  1985-06       Impact factor: 22.682

5.  Cimetidine or vagotomy? Comparison of the effects of proximal gastric vagotomy, cimetidine and placebo on nocturnal intragastric acidity and acid secretion in patients with cimetidine resistant duodenal ulcer.

Authors:  T Gledhill; M Buck; A Paul; R H Hunt
Journal:  Br J Surg       Date:  1983-12       Impact factor: 6.939

6.  Low dose omeprazole effects on gastric acid secretion in normal man.

Authors:  P Hemery; J P Galmiche; C Roze; J P Isal; S Bruley des Varannes; A Lavignolle; L Le Bodic
Journal:  Gastroenterol Clin Biol       Date:  1987-02

7.  Single dose treatment with H2 receptor antagonists: is bedtime administration too late?

Authors:  H Merki; L Witzel; K Harre; E Scheurle; J Neumann; J Röhmel
Journal:  Gut       Date:  1987-04       Impact factor: 23.059

8.  Comparison of the effects of gastric antisecretory agents in healthy volunteers and patients with duodenal ulcer.

Authors:  C W Howden; D B Jones; D W Burget; R H Hunt
Journal:  Gut       Date:  1986-09       Impact factor: 23.059

9.  [Does nocturnal monitoring of gastric pH permit the prediction of therapeutic response in severe duodenal ulcer treated with ranitidine?].

Authors:  J P Galmiche; J L Tranvouez; P Denis; C N'Djitoyap; J F Guillard; P A Lehur; R Colin
Journal:  Gastroenterol Clin Biol       Date:  1985 Aug-Sep
  9 in total
  1 in total

Review 1.  Roxatidine acetate. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic potential in peptic ulcer disease and related disorders.

Authors:  D Murdoch; D McTavish
Journal:  Drugs       Date:  1991-08       Impact factor: 9.546

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.